Inhibition of choroidal neovascularization via brief subretinal exposure to a newly developed lentiviral vector pseudotyped with sendai viral envelope proteins

Human Gene Therapy

Volumn 21, Issue 2, 2010, Pages 199-209

  Murakami, Yusuke ^a   Ikeda, Yasuhiro ^a   Yonemitsu, Yoshikazu ^b   Miyazaki, Masanori ^a   Inoue, Makoto ^c   Hasegawa, Mamoru ^c   Sueishi, Katsuo ^a   Ishibashi, Tatsuro ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c University of Tokyo   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GREEN FLUORESCENT PROTEIN; INDOCYANINE GREEN; LENTIVIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; GENE EXPRESSION; GENE TRANSFER; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INDOCYANINE GREEN ANGIOGRAPHY; LASER COAGULATION; LENTIVIRINAE; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SENDAI VIRUS; SUBRETINAL NEOVASCULARIZATION; TRANSGENE; TRANSMISSION ELECTRON MICROSCOPY; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE;

ANIMALS; CELL LINE; CHOROIDAL NEOVASCULARIZATION; EYE PROTEINS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; LENTIVIRUS; LUCIFERASES; MACULAR DEGENERATION; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS; PIGMENT EPITHELIUM OF EYE; RETINA; SENDAI VIRUS; SERPINS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS;

SENDAI VIRUS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 77249122269     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.102     Document Type: Article

References (66)

1. Acland, G.M., Aguirre, G.D., Ray, J., Zhang, Q., Aleman, T.S., Cideciyan, A.V., Pearce-Kelling, S.E., Anand, V., Zeng, Y., Maguire, A.M., Jacobson, S.G., Hauswirth, W.W., and Bennett, J. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95.
2. Avery, R.L., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Nasir, M.A., and Giust, M.J. (2006). Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113, 363-372, e365.
3. Bainbridge, J.W., Mistry, A., De Alwis, M., Paleolog, E., Baker, A., Thrasher, A.J., and Ali, R.R. (2002). Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 9, 320-326.
4. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S.S., Thrasher, A.J., Fitzke, F.W., Carter, B.J., Rubin, G.S., Moore, A.T., and Ali, R.R. (2008). Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239.
5. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., Ezzat, M.K., and Singh, R.J. (2007). Pharmacokinetics of intravitreal ranibizu-mab (Lucentis). Ophthalmology 114, 2179-2182.
6. Blaauwgeers, H.G., Holtkamp, G.M., Rutten, H., Witmer, A.N., Koolwijk, P., Partanen, T.A., Alitalo, K., Kroon, M.E., Kijlstra, A., Van Hinsbergh, V.W., and Schlingemann, R.O. (1999). Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: Evidence for a trophic paracrine relation. Am. J. Pathol. 155, 421-428.
7. Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y., Sy, J.P., and Schneider, S. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444.
8. Campochiaro, P.A., Nguyen, Q.D., Shah, S.M., Klein, M.L., Holz, E., Frank, R.N., Saperstein, D.A., Gupta, A., Stout, J.T., Macko, J., Dibartolomeo, R., and Wei, L.L. (2006). Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial. Hum. Gene Ther. 17, 167-176.
9. Cideciyan, A.V., Hauswirth, W.W., Aleman, T.S., Kaushal, S., Schwartz, S.B., Boye, S.L., Windsor, E.A., Conlon, T.J., Sumar-oka, A., Pang, J.J., Roman, A.J., Byrne, B.J., and Jacobson, S.G. (2009). Human RPE65 gene therapy for Leber congenital am-aurosis: Persistence of early visual improvements and safety at 1 year. Hum. Gene Ther. 20, 999-1004.
10. Darland, D.C., Massingham, L.J., Smith, S.R., Piek, E., Saint-Geniez, M., and D'Amore, P.A. (2003). Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev. Biol. 264, 275-288.
11. Dawson, D.W., Volpert, O.V., Gillis, P., Crawford, S.E., Xu, H., Benedict, W., and Bouck, N.P. (1999). Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 285, 245-248.
12. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
13. Friedman, D.S., O'Colmain, B.J., MunoZ, B., Tomany, S.C., Mccarty, C., De Jong, P.T., Nemesure, B., Mitchell, P., and Kempen, J. (2004). Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572. (Pubitemid 38456293)
14. Gehlbach, P., Demetriades, A.M., Yamamoto, S., Deering, T., Xiao, W.H., Duh, E.J., Yang, H.S., Lai, H., Kovesdi, I., Carrion, M., Wei, L., and Campochiaro, P.A. (2003). Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther. 14, 129-141.
15. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Jr., Feinsod, M., and Guyer, D.R. (2004). Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805-2816.
16. Hauswirth, W.W., Aleman, T.S., Kaushal, S., Cideciyan, A.V., Schwartz, S.B., Wang, L., Conlon, T.J., Boye, S.L., Flotte, T.R., Byrne, B.J., and Jacobson, S.G. (2008). Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular sub-retinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum. Gene Ther. 19, 979-990.
17. Honda, M., Sakamoto, T., Ishibashi, T., Inomata, H., and Ueno, H. (2000). Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF=flt-1 receptor gene transfection: A role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. 7, 978-985.
18. Hurwitz, H., and Saini, S. (2006). Bevacizumab in the treatment of metastatic colorectal cancer: Safety profile and management of adverse events. Semin. Oncol. 33, S26-S34.
19. Ikeda, Y., Yonemitsu, Y., Sakamoto, T., Ishibashi, T., Ueno, H., Kato, A., Nagai, Y., Fukumura, M., Inomata, H., Hasegawa, M., and Sueishi, K. (2002). Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: Efficient gene transfer by brief exposure. Exp. Eye Res. 75, 39-48.
20. Ikeda, Y., Goto, Y., Yonemitsu, Y., Miyazaki, M., Sakamoto, T., Ishibashi, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., and Sueishi, K. (2003). Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: A preclinical safety study in adult rats. Gene Ther. 10, 1161-1169.
21. Inan, U.U., Avci, B., Kusbeci, T., Kaderli, B., Avci, R., and Temel, S.G. (2007). Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest. Ophthalmol. Vis. Sci. 48, 1773-1781.
22. Ishibashi, T., Hata, Y., Yoshikawa, H., Nakagawa, K., Sueishi, K., and Inomata, H. (1997). Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 235, 159-167.
23. Jacobson, S.G., Acland, G.M., Aguirre, G.D., Aleman, T.S., Schwartz, S.B., Cideciyan, A.V., Zeiss, C.J., Komaromy, A.M., Kaushal, S., Roman, A.J., Windsor, E.A., Sumaroka, A., Pearce-Kelling, S.E., Conlon, T.J., Chiodo, V.A., Boye, S.L., Flotte, T.R., Maguire, A.M., Bennett, J., and Hauswirth, W.W. (2006a). Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol. Ther. 13, 1074-1084.
24. Jacobson, S.G., Boye, S.L., Aleman, T.S., Conlon, T.J., Zeiss, C.J., Roman, A.J., Cideciyan, A.V., Schwartz, S.B., Komaromy, A.M., Doobrajh, M., Cheung, A.Y., Sumaroka, A., Pearce-Kelling, S.E., Aguirre, G.D., Kaushal, S., Maguire, A.M., Flotte, T.R., and Hauswirth, W.W. (2006b). Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene Ther. 17, 845-858.
25. Janssen, A., Hoellenriegel, J., Fogarasi, M., Schrewe, H., Seeliger, M., Tamm, E., Ohlmann, A., May, C.A., Weber, B.H., and Stohr, H. (2008). Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3. Invest. Ophthal-mol. Vis. Sci. 49, 2812-2822.
26. Kendall, R.L., Wang, G., and Thomas, K.A. (1996). Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226, 324-328.
27. Kobayashi, M., Iida, A., Ueda, Y., and Hasegawa, M. (2003). Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J. Virol. 77, 2607-2614.
28. Krzystolik, M.G., Afshari, M.A., Adamis, A.P., Gaudreault, J., Gragoudas, E.S., Michaud, N.A., Li, W., Connolly, E., O'Neill, C.A., and Miller, J.W. (2002). Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthal-mol. 120, 338-346.
29. Lai, C.M., Shen, W.Y., Brankov, M., Lai, Y.K., Barnett, N.L., Lee, S.Y., Yeo, I.Y., Mathur, R., Ho, J.E., Pineda, P., Barathi, A., Ang, C.L., Constable, I.J., and Rakoczy, E.P. (2005). Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol. Ther. 12, 659-668.
30. Lai, Y.K., Shen, W.Y., Brankov, M., Lai, C.M., Constable, I.J., and Rakoczy, P.E. (2002). Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9, 804-813.
31. Lamb, R.A., and Kolakofsky, D. (1996). Paramyxoviridae: The viruses and their replication. In: Fields, B.N., Knipe, D.M., and Howley, P.M., eds. Fields Virology (Lippincott-Raven, Philadelphia, PA) pp. 1177-1204.
32. Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., De-sai, S., Ferrara, N., Nagy, A., Roos, K.P., and Iruela-Arispe, M.L. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
33. Levine, R.J., Maynard, S.E., Qian, C., Lim, K.H., England, L.J., Yu, K.F., Schisterman, E.F., Thadhani, R., Sachs, B.P., Epstein, F.H., Sibai, B.M., Sukhatme, V.P., and Karumanchi, S.A. (2004). Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683.
34. Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P., Lennartsson, J., Zhu, C., Qu, Y., Fang, C., Hua, J., Matsuo, O., Fong, G.H., Ding, H., Cao, Y., Becker, K.G., Nash, A., Heldin, C.H., and Li, X. (2008). VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J. Clin. Invest. 118, 913-923.
35. Lopez, P.F., Grossniklaus, H.E., Lambert, H.M., Aaberg, T.M., Capone, A., Jr., Sternberg, P., Jr., and L'Hernault, N. (1991). Pathologic features of surgically excised subretinal neovas-cular membranes in age-related macular degeneration. Am. J. Ophthalmol. 112, 647-656.
36. Maeda, Y., Ikeda, U., Shimpo, M., Ueno, S., Ogasawara, Y., Urabe, M., Kume, A., Takizawa, T., Saito, T., Colosi, P., Kurtzman, G., Shimada, K., and Ozawa, K. (1998). Efficient gene transfer into cardiac myocytes using adeno-associated virus (AAV) vectors. J. Mol. Cell. Cardiol. 30, 1341-1348.
37. Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N., Jr., Min-gozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Sur-ace, E.M., Rossi, S., Lyubarsky, A., Arruda, V.R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.X., Redmond, T.M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K.S., Maguire, M.G., Wright, J.F., Volpe, N.J., Mcdonnell, J.W., Auricchio, A., High, K.A., and Bennett, J. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248.
38. Maharaj, A.S., Walshe, T.E., Saint-Geniez, M., Venkatesha, S., Maldonado, A.E., Himes, N.C., Matharu, K.S., Karumanchi, S.A., and D'Amore, P.A. (2008). VEGF and TGF-b are required for the maintenance of the choroid plexus and ependyma. J. Exp. Med. 205, 491-501.
39. Marneros, A.G., Fan, J., Yokoyama, Y., Gerber, H.P., Ferrara, N., Crouch, R.K., and Olsen, B.R. (2005). Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am. J. Pathol. 167, 1451-1459.
40. Masaki, I., Yonemitsu, Y., Komori, K., Ueno, H., Nakashima, Y., Nakagawa, K., Fukumura, M., Kato, A., Hasan, M.K., Nagai, Y., Sugimachi, K., Hasegawa, M., and Sueishi, K. (2001). Recombinant Sendai virus-mediated gene transfer to vascula-ture: A new class of efficient gene transfer vector to the vascular system. FASEB J. 15, 1294-1296.
41. Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E., Epstein, F.H., Sukhatme, V.P., and Karumanchi, S.A. (2003). Excess placental soluble Fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and pro-teinuria in preeclampsia. J. Clin. Invest. 111, 649-658.
42. Miyazaki, M., Ikeda, Y., Yonemitsu, Y., Goto, Y., Sakamoto, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., Ishibashi, T., and Sueishi, K. (2003). Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of Surgeons rats. Gene Ther. 10, 1503-1511.
43. Miyazaki, M., Kiyohara, Y., Yoshida, A., Iida, M., Nose, Y., and Ishibashi, T. (2005). The 5-year incidence and risk factors for age-related maculopathy in a general Japanese population: The Hisayama Study. Invest. Ophthalmol. Vis. Sci. 46, 1907-1910.
44. Miyoshi, H., Takahashi, M., Gage, F.H., and Verma, I.M. (1997). Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 94, 10319-10323.
45. Mori, K., Gehlbach, P., Ando, A., Mcvey, D., Wei, L., and Cam-pochiaro, P.A. (2002). Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 43, 2428-2434.
46. Murakami, Y., Ikeda, Y., Yonemitsu, Y., Onimaru, M., Nakagawa, K., Kohno, R., Miyazaki, M., Hisatomi, T., Nakamura, M., Yabe, T., Hasegawa, M., Ishibashi, T., and Sueishi, K. (2008a) Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am. J. Pathol. 173, 1326-1338.
47. Murakami, Y., Ikeda, Y., Yonemitsu, Y., Tanaka, S., Kondo, H., Okano, S., Kohno, R., Miyazaki, M., Inoue, M., Hasegawa, M., Ishibashi, T., and Sueishi, K. (2008b). Newly-developed Sendai virus vector for retinal gene transfer: Reduction of innate immune response via deletion of all envelope-related genes. J. Gene Med. 10, 165-176.
48. Nishijima, K., Ng, Y.S., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S.J., Robinson, G.S., Adamis, A.P., and Shima, D.T. (2007). Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuro-protectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67.
49. Pechan, P., Rubin, H., Lukason, M., Ardinger, J., Dufresne, E., Hauswirth, W.W., Wadsworth, S.C., and Scaria, A. (2009). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 16, 10-16.
50. Peters, S., Heiduschka, P., Julien, S., Ziemssen, F., Fietz, H., Bartz-Schmidt, K.U., and Schraermeyer, U. (2007). Ultrastructural findings in the primate eye after intravitreal injection of bev-acizumab. Am. J. Ophthalmol. 143, 995-1002.
51. Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y., and Kim, R.Y. (2006). Ranibizumab for neovas-cular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431.
52. Saint-Geniez, M., Maldonado, A.E., and D'Amore, P.A. (2006). VEGF expression and receptor activation in the choroid during development and in the adult. Invest. Ophthalmol. Vis. Sci. 47, 3135-3142.
53. Saint-Geniez, M., Maharaj, A.S., Walshe, T.E., Tucker, B.A., Se-kiyama, E., Kurihara, T., Darland, D.C., Young, M.J., and D'Amore, P.A. (2008). Endogenous VEGF is required for visual function: Evidence for a survival role on muller cells and photoreceptors. PLoS ONE 3, e3554.
54. Sang, D.N., and D'Amore, P.A. (2008). Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 51, 1570-1573.
55. Steele, F.R., Chader, G.J., Johnson, L.V., and Tombran-Tink, J. (1993). Pigment epithelium-derived factor: Neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc. Natl. Acad. Sci. U.S.A. 90, 1526-1530.
56. Stitt, A.W., Simpson, D.A., Boocock, C., Gardiner, T.A., Murphy, G.M., and Archer, D.B. (1998). Expression of vascular endo-thelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J. Pathol. 186, 306-312.
57. Takahashi, H., and Shibuya, M. (2005). The vascular endothelial growth factor (VEGF)=VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109, 227-241.
58. Takita, H., Yoneya, S., Gehlbach, P.L., Duh, E.J., Wei, L.L., and Mori, K. (2003). Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 44, 4497-4504.
59. Taniwaki, T., Becerra, S.P., Chader, G.J., and Schwartz, J.P. (1995). Pigment epithelium-derived factor is a survival factor for cerebellar granule cells in culture. J. Neurochem. 64, 2509-2517.
60. Teramoto, S., Bartlett, J.S., Mccarty, D., Xiao, X., Samulski, R.J., and Boucher, R.C. (1998). Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors. J. Virol. 72, 8904-8912.
61. Tombran-Tink, J., and Johnson, L.V. (1989). Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest. Ophthalmol. Vis. Sci. 30, 1700-1707.
62. Tsutsumi, C., Sonoda, K.H., Egashira, K., Qiao, H., Hisatomi, T., Nakao, S., Ishibashi, M., Charo, I.F., Sakamoto, T., Murata, T., and Ishibashi, T. (2003). The critical role of ocular-infiltrating macrophages in the development of choroidal neovascular-ization. J. Leukoc. Biol. 74, 25-32.
63. Ueno, S., Pease, M.E., Wersinger, D.M., Masuda, T., Vinores, S.A., Licht, T., Zack, D.J., Quigley, H., Keshet, E., and Cam-pochiaro, P.A. (2008). Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J. Cell Physiol. 217, 13-22.
64. Volpert, O.V., Zaichuk, T., Zhou, W., Reiher, F., Ferguson, T.A., Stuart, P.M., Amin, M., and Bouck, N.P. (2002). Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8, 349-357.
65. Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P.K., Kato, A., Hasan, M.K., Nagai, Y., Masaki, I., Fukumura, M., Hasegawa, M., Geddes, D.M., and Alton, E.W. (2000). Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat. Biotechnol. 18, 970-973.
66. Zaichuk, T.A., Shroff, E.H., Emmanuel, R., Filleur, S., Nelius, T., and Volpert, O.V. (2004). Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J. Exp. Med. 199, 1513-1522.